nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—NFKB1—MAPK Signaling Pathway—TGFBR1—age related macular degeneration	0.00401	0.00401	CbGpPWpGaD
Thalidomide—NFKB1—MyD88:Mal cascade initiated on plasma membrane—CD36—age related macular degeneration	0.00388	0.00388	CbGpPWpGaD
Thalidomide—NFKB1—Oncostatin M Signaling Pathway—CCL2—age related macular degeneration	0.00386	0.00386	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—CCL2—age related macular degeneration	0.00381	0.00381	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—C9—age related macular degeneration	0.00379	0.00379	CbGpPWpGaD
Thalidomide—NFKB1—Selenium Micronutrient Network—CRP—age related macular degeneration	0.00368	0.00368	CbGpPWpGaD
Thalidomide—CYP1A1—Melatonin metabolism and effects—APOE—age related macular degeneration	0.00366	0.00366	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TGFBR1—age related macular degeneration	0.00362	0.00362	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—C9—age related macular degeneration	0.0036	0.0036	CbGpPWpGaD
Thalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—age related macular degeneration	0.00359	0.00359	CbGpPWpGaD
Thalidomide—TNF—Vitamin B12 Metabolism—CCL2—age related macular degeneration	0.00357	0.00357	CbGpPWpGaD
Thalidomide—TNF—Folate Metabolism—CRP—age related macular degeneration	0.00353	0.00353	CbGpPWpGaD
Thalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—CD36—age related macular degeneration	0.00346	0.00346	CbGpPWpGaD
Thalidomide—NFKB1—Corticotropin-releasing hormone—TLR4—age related macular degeneration	0.00341	0.00341	CbGpPWpGaD
Thalidomide—NFKB1—MyD88:Mal cascade initiated on plasma membrane—TLR4—age related macular degeneration	0.00335	0.00335	CbGpPWpGaD
Thalidomide—NFKB1—Activated TLR4 signalling—CD36—age related macular degeneration	0.00334	0.00334	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CFI—age related macular degeneration	0.00329	0.00329	CbGpPWpGaD
Thalidomide—NFKB1—Aryl Hydrocarbon Receptor—VEGFA—age related macular degeneration	0.00327	0.00327	CbGpPWpGaD
Thalidomide—PTGS2—Aryl Hydrocarbon Receptor—CD36—age related macular degeneration	0.00323	0.00323	CbGpPWpGaD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—SQSTM1—age related macular degeneration	0.00322	0.00322	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—C3—age related macular degeneration	0.00322	0.00322	CbGpPWpGaD
Thalidomide—CYP2E1—Vitamin A and Carotenoid Metabolism—CD36—age related macular degeneration	0.00321	0.00321	CbGpPWpGaD
Thalidomide—NFKB1—MyD88-independent cascade—TLR4—age related macular degeneration	0.00321	0.00321	CbGpPWpGaD
Thalidomide—NFKB1—Toll Like Receptor 4 (TLR4) Cascade—CD36—age related macular degeneration	0.00315	0.00315	CbGpPWpGaD
Thalidomide—NFKB1—Toll-like Receptor Signaling Pathway—TLR4—age related macular degeneration	0.00314	0.00314	CbGpPWpGaD
Thalidomide—PTGS2—S1P1 pathway—VEGFA—age related macular degeneration	0.00312	0.00312	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CFI—age related macular degeneration	0.00312	0.00312	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—CST3—age related macular degeneration	0.00307	0.00307	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CFHR3—age related macular degeneration	0.00306	0.00306	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—TGFBR1—age related macular degeneration	0.00305	0.00305	CbGpPWpGaD
Thalidomide—NFKB1—Selenium Micronutrient Network—CCL2—age related macular degeneration	0.00303	0.00303	CbGpPWpGaD
Thalidomide—CYP2C19—Melatonin metabolism and effects—APOE—age related macular degeneration	0.003	0.003	CbGpPWpGaD
Thalidomide—TNF—Alzheimers Disease—APOE—age related macular degeneration	0.00299	0.00299	CbGpPWpGaD
Thalidomide—NFKB1—TNF alpha Signaling Pathway—CCL2—age related macular degeneration	0.00292	0.00292	CbGpPWpGaD
Thalidomide—TNF—Folate Metabolism—CCL2—age related macular degeneration	0.00291	0.00291	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CFHR3—age related macular degeneration	0.0029	0.0029	CbGpPWpGaD
Thalidomide—NFKB1—Activated TLR4 signalling—TLR4—age related macular degeneration	0.00289	0.00289	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—CD36—age related macular degeneration	0.00287	0.00287	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—CRP—age related macular degeneration	0.00281	0.00281	CbGpPWpGaD
Thalidomide—NFKB1—Toll-Like Receptors Cascades—CD36—age related macular degeneration	0.0028	0.0028	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—TGFBR1—age related macular degeneration	0.00276	0.00276	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—C2—age related macular degeneration	0.00273	0.00273	CbGpPWpGaD
Thalidomide—NFKB1—Toll Like Receptor 4 (TLR4) Cascade—TLR4—age related macular degeneration	0.00272	0.00272	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—C2—age related macular degeneration	0.00259	0.00259	CbGpPWpGaD
Thalidomide—TNF—Aryl Hydrocarbon Receptor—VEGFA—age related macular degeneration	0.00249	0.00249	CbGpPWpGaD
Thalidomide—NFKB1—Oncostatin M Signaling Pathway—VEGFA—age related macular degeneration	0.00248	0.00248	CbGpPWpGaD
Thalidomide—NFKB1—Regulation of toll-like receptor signaling pathway—TLR4—age related macular degeneration	0.00245	0.00245	CbGpPWpGaD
Thalidomide—NFKB1—Toll-Like Receptors Cascades—TLR4—age related macular degeneration	0.00242	0.00242	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—SQSTM1—age related macular degeneration	0.00241	0.00241	CbGpPWpGaD
Thalidomide—TNF—Toll-like Receptor Signaling Pathway—TLR4—age related macular degeneration	0.00239	0.00239	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—SQSTM1—age related macular degeneration	0.00237	0.00237	CbGpPWpGaD
Thalidomide—CYP1A2—Melatonin metabolism and effects—APOE—age related macular degeneration	0.00234	0.00234	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—CCL2—age related macular degeneration	0.00231	0.00231	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CFH—age related macular degeneration	0.00228	0.00228	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—ELOVL4—age related macular degeneration	0.00228	0.00228	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—SQSTM1—age related macular degeneration	0.00225	0.00225	CbGpPWpGaD
Thalidomide—TNF—TNF alpha Signaling Pathway—CCL2—age related macular degeneration	0.00223	0.00223	CbGpPWpGaD
Thalidomide—FGFR2—Disease—RDH8—age related macular degeneration	0.00221	0.00221	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NMNAT1—age related macular degeneration	0.00221	0.00221	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CFB—age related macular degeneration	0.00221	0.00221	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—C9—age related macular degeneration	0.00221	0.00221	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—CRP—age related macular degeneration	0.00219	0.00219	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CFH—age related macular degeneration	0.00216	0.00216	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—TLR4—age related macular degeneration	0.00213	0.00213	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CFB—age related macular degeneration	0.0021	0.0021	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—C9—age related macular degeneration	0.0021	0.0021	CbGpPWpGaD
Thalidomide—FGFR2—Ectoderm Differentiation—CCL2—age related macular degeneration	0.00201	0.00201	CbGpPWpGaD
Thalidomide—FGFR2—Disease—RPE65—age related macular degeneration	0.00194	0.00194	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CFI—age related macular degeneration	0.00192	0.00192	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CST3—age related macular degeneration	0.0019	0.0019	CbGpPWpGaD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—TLR4—age related macular degeneration	0.00187	0.00187	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—CD36—age related macular degeneration	0.00183	0.00183	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—CCL2—age related macular degeneration	0.00183	0.00183	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CFI—age related macular degeneration	0.00182	0.00182	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—ELOVL4—age related macular degeneration	0.00181	0.00181	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—CCL2—age related macular degeneration	0.0018	0.0018	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CFHR3—age related macular degeneration	0.00178	0.00178	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—CRP—age related macular degeneration	0.00174	0.00174	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFBR1—age related macular degeneration	0.0017	0.0017	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CFHR3—age related macular degeneration	0.00169	0.00169	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—RDH8—age related macular degeneration	0.00163	0.00163	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—VEGFA—age related macular degeneration	0.00162	0.00162	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—ELOVL4—age related macular degeneration	0.0016	0.0016	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—C2—age related macular degeneration	0.00159	0.00159	CbGpPWpGaD
Thalidomide—FGFR2—Disease—ABCA4—age related macular degeneration	0.00156	0.00156	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—RDH8—age related macular degeneration	0.00155	0.00155	CbGpPWpGaD
Thalidomide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—age related macular degeneration	0.00154	0.00154	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—C2—age related macular degeneration	0.00151	0.00151	CbGpPWpGaD
Thalidomide—CYP1A1—PPARA activates gene expression—CD36—age related macular degeneration	0.00143	0.00143	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—RPE65—age related macular degeneration	0.00143	0.00143	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—CCL2—age related macular degeneration	0.00143	0.00143	CbGpPWpGaD
Thalidomide—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CD36—age related macular degeneration	0.0014	0.0014	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—age related macular degeneration	0.00137	0.00137	CbGpPWpGaD
Thalidomide—FGFR2—Disease—RHO—age related macular degeneration	0.00136	0.00136	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—RPE65—age related macular degeneration	0.00136	0.00136	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CFH—age related macular degeneration	0.00133	0.00133	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TLR4—age related macular degeneration	0.00132	0.00132	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—ELOVL4—age related macular degeneration	0.00131	0.00131	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CFB—age related macular degeneration	0.00129	0.00129	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—VEGFA—age related macular degeneration	0.00126	0.00126	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CFH—age related macular degeneration	0.00126	0.00126	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—VEGFA—age related macular degeneration	0.00123	0.00123	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CFB—age related macular degeneration	0.00122	0.00122	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—ELOVL4—age related macular degeneration	0.0012	0.0012	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—NMNAT1—age related macular degeneration	0.00116	0.00116	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ABCA4—age related macular degeneration	0.00115	0.00115	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—CCL2—age related macular degeneration	0.00113	0.00113	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NMNAT1—age related macular degeneration	0.0011	0.0011	CbGpPWpGaD
Thalidomide—PTGS2—Disease—RDH8—age related macular degeneration	0.0011	0.0011	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ABCA4—age related macular degeneration	0.00109	0.00109	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—VEGFA—age related macular degeneration	0.00105	0.00105	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—CD36—age related macular degeneration	0.00103	0.00103	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ELOVL4—age related macular degeneration	0.00102	0.00102	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ELOVL4—age related macular degeneration	0.00101	0.00101	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—RHO—age related macular degeneration	0.001	0.001	CbGpPWpGaD
Thalidomide—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CD36—age related macular degeneration	0.000964	0.000964	CbGpPWpGaD
Thalidomide—PTGS2—Disease—RPE65—age related macular degeneration	0.000961	0.000961	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—RHO—age related macular degeneration	0.00095	0.00095	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—LIPC—age related macular degeneration	0.00094	0.00094	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—VEGFA—age related macular degeneration	0.000938	0.000938	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—NMNAT1—age related macular degeneration	0.000921	0.000921	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CD36—age related macular degeneration	0.000908	0.000908	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—CETP—age related macular degeneration	0.000906	0.000906	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—KDR—age related macular degeneration	0.000888	0.000888	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—age related macular degeneration	0.000872	0.000872	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CD36—age related macular degeneration	0.000872	0.000872	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—NMNAT1—age related macular degeneration	0.000867	0.000867	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—NMNAT1—age related macular degeneration	0.000865	0.000865	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CD36—age related macular degeneration	0.000861	0.000861	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—C3—age related macular degeneration	0.00086	0.00086	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CST3—age related macular degeneration	0.000849	0.000849	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CD36—age related macular degeneration	0.000827	0.000827	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—C3—age related macular degeneration	0.000826	0.000826	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CRP—age related macular degeneration	0.000818	0.000818	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—NMNAT1—age related macular degeneration	0.000817	0.000817	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—SLC16A8—age related macular degeneration	0.000817	0.000817	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—C3—age related macular degeneration	0.000816	0.000816	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—VEGFA—age related macular degeneration	0.000808	0.000808	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ELOVL4—age related macular degeneration	0.000805	0.000805	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—VEGFA—age related macular degeneration	0.000797	0.000797	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—SQSTM1—age related macular degeneration	0.000789	0.000789	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—TLR4—age related macular degeneration	0.000784	0.000784	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—C3—age related macular degeneration	0.000784	0.000784	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—CD36—age related macular degeneration	0.000783	0.000783	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CRP—age related macular degeneration	0.000776	0.000776	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ABCA4—age related macular degeneration	0.000775	0.000775	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TGFBR1—age related macular degeneration	0.000762	0.000762	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ELOVL4—age related macular degeneration	0.000758	0.000758	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ELOVL4—age related macular degeneration	0.000756	0.000756	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—SQSTM1—age related macular degeneration	0.000748	0.000748	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—LIPC—age related macular degeneration	0.000746	0.000746	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—TLR4—age related macular degeneration	0.000744	0.000744	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—CETP—age related macular degeneration	0.00072	0.00072	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ELOVL4—age related macular degeneration	0.000714	0.000714	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—KDR—age related macular degeneration	0.000677	0.000677	CbGpPWpGaD
Thalidomide—PTGS2—Disease—RHO—age related macular degeneration	0.000674	0.000674	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NMNAT1—age related macular degeneration	0.000669	0.000669	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—LIPC—age related macular degeneration	0.000662	0.000662	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—SLC16A8—age related macular degeneration	0.000649	0.000649	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—CETP—age related macular degeneration	0.000639	0.000639	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—SLC16A8—age related macular degeneration	0.000611	0.000611	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NMNAT1—age related macular degeneration	0.00061	0.00061	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—SLC16A8—age related macular degeneration	0.00061	0.00061	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ELOVL4—age related macular degeneration	0.000585	0.000585	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—SLC16A8—age related macular degeneration	0.000576	0.000576	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TGFBR1—age related macular degeneration	0.000562	0.000562	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—CD36—age related macular degeneration	0.000545	0.000545	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—LIPC—age related macular degeneration	0.000542	0.000542	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TGFBR1—age related macular degeneration	0.000534	0.000534	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ELOVL4—age related macular degeneration	0.000533	0.000533	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD36—age related macular degeneration	0.000529	0.000529	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—CETP—age related macular degeneration	0.000523	0.000523	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NMNAT1—age related macular degeneration	0.000521	0.000521	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SQSTM1—age related macular degeneration	0.00051	0.00051	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD36—age related macular degeneration	0.000502	0.000502	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—C3—age related macular degeneration	0.000501	0.000501	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—LIPC—age related macular degeneration	0.000494	0.000494	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—age related macular degeneration	0.000493	0.000493	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—VEGFA—age related macular degeneration	0.000489	0.000489	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SQSTM1—age related macular degeneration	0.000484	0.000484	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—APOE—age related macular degeneration	0.000481	0.000481	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CRP—age related macular degeneration	0.000477	0.000477	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—CETP—age related macular degeneration	0.000477	0.000477	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—C3—age related macular degeneration	0.000475	0.000475	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—SLC16A8—age related macular degeneration	0.000471	0.000471	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—TLR4—age related macular degeneration	0.000457	0.000457	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ELOVL4—age related macular degeneration	0.000456	0.000456	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CRP—age related macular degeneration	0.000452	0.000452	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—TLR4—age related macular degeneration	0.000434	0.000434	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—CD36—age related macular degeneration	0.000432	0.000432	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SLC16A8—age related macular degeneration	0.00043	0.00043	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—LIPC—age related macular degeneration	0.000422	0.000422	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CST3—age related macular degeneration	0.000421	0.000421	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—LIPC—age related macular degeneration	0.000418	0.000418	CbGpPWpGaD
Thalidomide—FGFR2—Disease—APOE—age related macular degeneration	0.000409	0.000409	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CETP—age related macular degeneration	0.000407	0.000407	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CETP—age related macular degeneration	0.000404	0.000404	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—CD36—age related macular degeneration	0.000384	0.000384	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOE—age related macular degeneration	0.000382	0.000382	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TGFBR1—age related macular degeneration	0.000378	0.000378	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—VEGFA—age related macular degeneration	0.000373	0.000373	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SLC16A8—age related macular degeneration	0.000367	0.000367	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—APOE—age related macular degeneration	0.000339	0.000339	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—LIPC—age related macular degeneration	0.000332	0.000332	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—C3—age related macular degeneration	0.000324	0.000324	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CETP—age related macular degeneration	0.00032	0.00032	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—CD36—age related macular degeneration	0.000314	0.000314	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—LIPC—age related macular degeneration	0.000313	0.000313	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—LIPC—age related macular degeneration	0.000312	0.000312	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—C3—age related macular degeneration	0.000307	0.000307	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CETP—age related macular degeneration	0.000302	0.000302	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—APOE—age related macular degeneration	0.000302	0.000302	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CETP—age related macular degeneration	0.000301	0.000301	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KDR—age related macular degeneration	0.000295	0.000295	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—LIPC—age related macular degeneration	0.000295	0.000295	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—CD36—age related macular degeneration	0.000286	0.000286	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—APOE—age related macular degeneration	0.000286	0.000286	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CETP—age related macular degeneration	0.000284	0.000284	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KDR—age related macular degeneration	0.00028	0.00028	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—age related macular degeneration	0.000277	0.000277	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCL2—age related macular degeneration	0.000253	0.000253	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—age related macular degeneration	0.000253	0.000253	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CD36—age related macular degeneration	0.000245	0.000245	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CD36—age related macular degeneration	0.000243	0.000243	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—LIPC—age related macular degeneration	0.000241	0.000241	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCL2—age related macular degeneration	0.00024	0.00024	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CETP—age related macular degeneration	0.000233	0.000233	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—LIPC—age related macular degeneration	0.00022	0.00022	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—age related macular degeneration	0.000216	0.000216	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—APOE—age related macular degeneration	0.000214	0.000214	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CETP—age related macular degeneration	0.000212	0.000212	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APOE—age related macular degeneration	0.000203	0.000203	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CD36—age related macular degeneration	0.000193	0.000193	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—LIPC—age related macular degeneration	0.000188	0.000188	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CETP—age related macular degeneration	0.000181	0.000181	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CD36—age related macular degeneration	0.000181	0.000181	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CD36—age related macular degeneration	0.000181	0.000181	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CD36—age related macular degeneration	0.000171	0.000171	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—APOE—age related macular degeneration	0.00017	0.00017	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—VEGFA—age related macular degeneration	0.000163	0.000163	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOE—age related macular degeneration	0.00016	0.00016	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOE—age related macular degeneration	0.00016	0.00016	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VEGFA—age related macular degeneration	0.000154	0.000154	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOE—age related macular degeneration	0.000151	0.000151	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CD36—age related macular degeneration	0.00014	0.00014	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CD36—age related macular degeneration	0.000128	0.000128	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOE—age related macular degeneration	0.000123	0.000123	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOE—age related macular degeneration	0.000113	0.000113	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CD36—age related macular degeneration	0.000109	0.000109	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOE—age related macular degeneration	9.62e-05	9.62e-05	CbGpPWpGaD
